Frontiers in the treatment of hepatitis c virus infection

Joseph Ahn, Steven L. Flamm

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In the United States, chronic hepatitis C virus (HCV) infection is the leading cause of blood-borne, virus-associated death related to advanced liver disease and the leading indication for liver transplantation. Although the diagnostic test for HCV has been available for more than 20 years, the majority of persons with HCV infection still have not received a diagnosis. This has led to a recent change in screening recommendations by the Centers for Disease Control and Prevention. Moreover, new medications were approved in 2011 after nearly a decade of minimal progress in the development of treatments for HCV infection. This was followed by the highly anticipated approval of sofosbuvir and simeprevir in 2013. In the past 3 years, there has been an explo sion of reports on medications from different classes, promising a dramatic expansion to an all-oral regimen for the treatment of HCV genotype 1 infection within the next few years. This article reviews the current screening recommendations and standard of care for treatment of HCV infection and highlights specific agents in the pipeline that should change the landscape of how HCV infection is treated in the near future.

Original languageEnglish (US)
Pages (from-to)90-100
Number of pages11
JournalGastroenterology and Hepatology
Volume10
Issue number2
StatePublished - Feb 2014

Fingerprint

Hepatitis Viruses
Virus Diseases
Hepacivirus
Therapeutics
Chronic Hepatitis C
Standard of Care
Centers for Disease Control and Prevention (U.S.)
Routine Diagnostic Tests
Liver Transplantation
Liver Diseases
Genotype
Viruses
Infection

Keywords

  • Direct-acting antiviral therapy
  • Hepatitis C virus
  • Interferon
  • NS3/4A protease inhibitors
  • NS5A inhibitors
  • NS5B inhibitors
  • Sofosbuvir

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Frontiers in the treatment of hepatitis c virus infection. / Ahn, Joseph; Flamm, Steven L.

In: Gastroenterology and Hepatology, Vol. 10, No. 2, 02.2014, p. 90-100.

Research output: Contribution to journalArticle

@article{f3b16ad5b6094da1831024d245229b5e,
title = "Frontiers in the treatment of hepatitis c virus infection",
abstract = "In the United States, chronic hepatitis C virus (HCV) infection is the leading cause of blood-borne, virus-associated death related to advanced liver disease and the leading indication for liver transplantation. Although the diagnostic test for HCV has been available for more than 20 years, the majority of persons with HCV infection still have not received a diagnosis. This has led to a recent change in screening recommendations by the Centers for Disease Control and Prevention. Moreover, new medications were approved in 2011 after nearly a decade of minimal progress in the development of treatments for HCV infection. This was followed by the highly anticipated approval of sofosbuvir and simeprevir in 2013. In the past 3 years, there has been an explo sion of reports on medications from different classes, promising a dramatic expansion to an all-oral regimen for the treatment of HCV genotype 1 infection within the next few years. This article reviews the current screening recommendations and standard of care for treatment of HCV infection and highlights specific agents in the pipeline that should change the landscape of how HCV infection is treated in the near future.",
keywords = "Direct-acting antiviral therapy, Hepatitis C virus, Interferon, NS3/4A protease inhibitors, NS5A inhibitors, NS5B inhibitors, Sofosbuvir",
author = "Joseph Ahn and Flamm, {Steven L.}",
year = "2014",
month = "2",
language = "English (US)",
volume = "10",
pages = "90--100",
journal = "Gastroenterology and Hepatology",
issn = "1554-7914",
publisher = "Gastro-Hep Communications, Inc.",
number = "2",

}

TY - JOUR

T1 - Frontiers in the treatment of hepatitis c virus infection

AU - Ahn, Joseph

AU - Flamm, Steven L.

PY - 2014/2

Y1 - 2014/2

N2 - In the United States, chronic hepatitis C virus (HCV) infection is the leading cause of blood-borne, virus-associated death related to advanced liver disease and the leading indication for liver transplantation. Although the diagnostic test for HCV has been available for more than 20 years, the majority of persons with HCV infection still have not received a diagnosis. This has led to a recent change in screening recommendations by the Centers for Disease Control and Prevention. Moreover, new medications were approved in 2011 after nearly a decade of minimal progress in the development of treatments for HCV infection. This was followed by the highly anticipated approval of sofosbuvir and simeprevir in 2013. In the past 3 years, there has been an explo sion of reports on medications from different classes, promising a dramatic expansion to an all-oral regimen for the treatment of HCV genotype 1 infection within the next few years. This article reviews the current screening recommendations and standard of care for treatment of HCV infection and highlights specific agents in the pipeline that should change the landscape of how HCV infection is treated in the near future.

AB - In the United States, chronic hepatitis C virus (HCV) infection is the leading cause of blood-borne, virus-associated death related to advanced liver disease and the leading indication for liver transplantation. Although the diagnostic test for HCV has been available for more than 20 years, the majority of persons with HCV infection still have not received a diagnosis. This has led to a recent change in screening recommendations by the Centers for Disease Control and Prevention. Moreover, new medications were approved in 2011 after nearly a decade of minimal progress in the development of treatments for HCV infection. This was followed by the highly anticipated approval of sofosbuvir and simeprevir in 2013. In the past 3 years, there has been an explo sion of reports on medications from different classes, promising a dramatic expansion to an all-oral regimen for the treatment of HCV genotype 1 infection within the next few years. This article reviews the current screening recommendations and standard of care for treatment of HCV infection and highlights specific agents in the pipeline that should change the landscape of how HCV infection is treated in the near future.

KW - Direct-acting antiviral therapy

KW - Hepatitis C virus

KW - Interferon

KW - NS3/4A protease inhibitors

KW - NS5A inhibitors

KW - NS5B inhibitors

KW - Sofosbuvir

UR - http://www.scopus.com/inward/record.url?scp=84896701990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896701990&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 90

EP - 100

JO - Gastroenterology and Hepatology

JF - Gastroenterology and Hepatology

SN - 1554-7914

IS - 2

ER -